Silexion Therapeutics Corp
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2024 | 2023 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(16,519) | $(5,108) |
| Adjustments required to reconcile loss to net cash used in operating activities: | ||
| Depreciation | 25 | 45 |
| Share-based compensation expenses | 5,862 | 130 |
| Non-cash loss upon entering Transactions | 4,783 | - |
| Other non-cash financial expenses (income) | (1,051) | 318 |
| Loss (gain) on disposal of property and equipment | 16 | (1) |
| Loss from lease termination | 68 | - |
| Changes in operating assets and liabilities: | ||
| Increase in prepaid expenses | (631) | (329) |
| Decrease (increase) in other current assets | (38) | 18 |
| Increase in trade payable | 610 | 79 |
| Net change in operating lease | (57) | 6 |
| Increase (decrease) in employee related obligations | 435 | (46) |
| Increase (decrease) in accrued expenses and other accounts payable | (1,899) | 359 |
| Net cash used in operating activities | (8,396) | (4,529) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from short-term deposit | - | 507 |
| Purchase of property and equipment | (22) | (12) |
| Proceeds from sale of property and equipment | - | 78 |
| Net cash provided by (used in) investing activities | (22) | 573 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of preferred shares and warrants, net of issuance costs | - | 522 |
| Proceeds from exercise of pre-funded options | * | - |
| Net proceeds from issuance of ordinary shares (ELOC) | 3,054 | - |
| Cash received from Transactions upon the effectiveness of the SPAC Merger | 2,300 | - |
| Payment of Underwriters Promissory Note | (250) | - |
| Net cash provided by financing activities | 5,104 | 522 |
| DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (3,314) | (3,434) |
| EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (61) | (230) |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR | 4,645 | 8,309 |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR | $1,270 | $4,645 |
CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2024 | 2023 | |
|---|---|---|
| Appendix A - | ||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS: | ||
| Cash and cash equivalents | 1,187 | 4,595 |
| Restricted cash | 83 | 50 |
| TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS | $1,270 | $4,645 |
| Appendix B - SUPPLEMENTARY INFORMATION: | ||
| SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: | ||
| Derecognition of right-of-use asset recognized and lease liability as a result of operating lease termination | $(89) | - |
| Conversion of preferred shares to ordinary shares | $15,391 | - |
| Conversion of warrants to preferred shares on a cashless basis | $334 | - |
| Conversion of non-controlling interests to New Silexion ordinary shares | $3,344 | - |
| Shares issued for ELOC financing liability | $312 | - |
| Right-of-use asset recognized with a corresponding lease liability | $506 | - |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||
| Interest paid | $27 | - |
| Interest received | $28 | $153 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.